3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Monoclonal antibody 3F8 (Primary) ; Tretinoin (Primary)
- Indications Cancer metastases; Neuroblastoma
- Focus Therapeutic Use
- 19 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
- 19 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 21 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.